Therapeutic potential of cannabinoid receptor agonists as analgesic agents
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Increasing data emerging from controlled clinical trials support an analgesic activity of cannabinoids. However, the psychotropic side effects associated with tetrahydrocannabinol or synthetic derivatives essentially puts a brake on their use, possibly limiting the degree of analgesia that can be achieved as well as providing regulatory hurdles. Animal studies show that although these side effects are mediated via central cannabinoid type 1 (CB(1)) receptors, the analgesic activity in chronic pain states may be mediated via spinal CB(1) and potentially CB(2) receptors, as well as peripheral CB(1) and CB2 receptors on sensory nerves or immune cells. The design of novel compounds that either specifically target peripheral CB(1) receptors or display high selectivity for CB(2) receptors may offer avenues for harnessing the analgesic effect of CB receptor agonists while avoiding the central adverse events seen with cannabinoid structures. Clinical trials with such compounds are required to determine whether either approach can provide the level of analgesia required to fulfil the unmet medical need left by current therapies for chronic pain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Herkenham, M., Lynn, A., Johnson, M., Melvin, L., de Costa, B., & Rice, K. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-02-00563.1991 · Cited by 2,159 · cited 1×
“CB1 receptors are predominantly localised to neurons of the central and peripheral nervous systems where they inhibit neuronal activity, although CB1 receptor mRNA has also been reported in non-neuronal cells in tissues such as the prostate, testes and vasculature and cells of the immune system [2-5].”
BackgroundImmunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system
Tsou, K., Brown, S., Sañudo-Peña, M. C., Mackie, K., & Walker, J. M. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00436-3 · Cited by 1,586
Lo Verme, J., Fu, J., Astarita, G., La Rana, G., Russo, R., Calignano, A., & Piomelli, D. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.006353 · Cited by 882
Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., & Thompson, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14738-1 · Cited by 827
Facci, L., Dal Toso, R., Romanello, S., Buriani, A., Skaper, S. D., & Leon, A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.8.3376 · Cited by 632
Svendsen, K. B., Jensen, T. S., & Bach, F. W. (2004) · BMJ · doi:10.1136/bmj.38149.566979.ae · Cited by 500 · cited 1×
“In a large study examining the activity of oral THC or cannabis extract in 611 multiple sclerosis patients there was a significant improvement in pain, recorded as a secondary measure [67], and a trial specifically looking at central pain in 21 patients with multiple sclerosis demonstrated a modest but clinically rele…”
BackgroundZhang, J., Hoffert, C., Vu, H. K., Groblewski, T., Ahmad, S., & O'Donnell, D. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02704.x · Cited by 419
The analgesic properties of delta‐9‐tetrahydrocannabinol and codeine
Noyes, R., Brunk, S. F., Avery, D. H., & Canter, A. (1975) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt197518184 · Cited by 378
Berman, J. S., Symonds, C., & Birch, R. (2004) · Pain · doi:10.1016/j.pain.2004.09.013 · Cited by 362 · cited 1×
“Both THC and GW-1000 (Sativex; a 1:1 mixture of THC and cannabidiol) administered sublingually were reported to give significant pain relief in cross-over trials in patients with pain due to multiple sclerosis or traumatic nerve injury [63,64], but were not effective in a cross-over trial of 48 patients with neuropath…”
BackgroundKarst, M., Salim, K., Burstein, S., Conrad, I., Hoy, L., & Schneider, U. (2003) · JAMA · doi:10.1001/jama.290.13.1757 · Cited by 340
Herzberg, U., Eliav, E., Bennett, G. J., & Kopin, I. J. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(96)13308-5 · Cited by 307 · cited 1×
“In models of neuropathic pain, cannabinoid ligands have similarly been shown to reduce allodynia or hyperalgesia [27-29].”
BackgroundNotcutt, W., Price, M., Miller, R., Newport, S., Phillips, C., Simmons, S., & Sansom, C. (2004) · Anaesthesia · doi:10.1111/j.1365-2044.2004.03674.x · Cited by 305 · cited 1×
“Both THC and GW-1000 (Sativex; a 1:1 mixture of THC and cannabidiol) administered sublingually were reported to give significant pain relief in cross-over trials in patients with pain due to multiple sclerosis or traumatic nerve injury [63,64], but were not effective in a cross-over trial of 48 patients with neuropath…”
BackgroundLichtman, A. H., Shelton, C. C., Advani, T., & Cravatt, B. F. (2004) · Pain · doi:10.1016/j.pain.2004.01.022 · Cited by 301 · cited 1×
“A similar increase in brain anandamide levels was seen in mice lacking FAAH, although there was no difference in the development of hyperalgesia in a model of neuropathic pain [79].”
BackgroundHohmann, A. G., & Herkenham, M. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00524-7 · Cited by 301
CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain
Clayton, N., Marshall, F. H., Bountra, C., & O'Shaughnessy, C. T. (2002) · Pain · doi:10.1016/s0304-3959(01)00454-7 · Cited by 247
The endogenous cannabinoid system and its role in nociceptive behavior
Cravatt, B. F., & Lichtman, A. H. (2004) · Journal of Neurobiology · doi:10.1002/neu.20080 · Cited by 203 · cited 1×
“In addition to these exogenous ligands, a number of fatty acid amide ‘endocannabinoids’ have been isolated from brain or gut tissue, including anandamide, 2-arachidonylglycerol (2-AG), noladin ether and virodhamine, which have varying affinities for CB1 and CB2 receptors [9,10].”
BackgroundLim, G., Sung, B., Ji, R.-R., & Mao, J. (2003) · Pain · doi:10.1016/s0304-3959(03)00242-2 · Cited by 195 · cited 13×
“STRANGMAN NM, WALKER JM: Cannabinoid WIN-55212-2 inhibits the activity dependent facilitation of spinal nociceptive responses.”
BackgroundInfluentialAntinociceptive Synergy between Δ9-Tetrahydrocannabinol and Opioids after Oral Administration
Cichewicz, D. L., & McCarthy, E. A. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.045575 · Cited by 154
Strangman, N. M., & Walker, J. M. (1999) · Journal of Neurophysiology · doi:10.1152/jn.1999.82.1.472 · Cited by 81 · cited 1×
“In addition, WIN-55212-2 inhibits the wind-up response of dorsal horn neurons to prolonged noxious stimulation [37], as well as capsaicin-induced peptide release in the spinal cord [24] and formalin-induced expression of c-fos, a marker of persistent noxious stimulation, in the spinal cord and thalamus [18,20].”
Background
Cited by
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
“Numerous early studies have also demonstrated beneficial effects of cannabinoids in animal models of pain (reviewed in Walker and Huang, 2002; Fox and Bevan, 2005).”
BackgroundPertwee, R. G. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707442 · Cited by 1,935
Emerging strategies for exploiting cannabinoid receptor agonists as medicines
Pertwee, R. G. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00048.x · Cited by 436
“…eccrine sweat glands, and second, that cutaneous CB1 and CB2 receptor activation produces antinociception in preclinical models of acute, inflammatory and neuropathic pain (Ständer et al., 2005; see Pertwee, 2001; Fox and Bevan, 2005; Whiteside et al., 2007; Guindon and Hohmann, 2008 for reviews).”
BackgroundLigands that target cannabinoid receptors in the brain: from THC to anandamide and beyond
Pertwee, R. G. (2008) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00108.x · Cited by 314
Staton, P. C., Hatcher, J. P., Walker, D. J., Morrison, A. D., Shapland, E. M., Hughes, J. P., Chong, E., Mander, P. K., Green, P. J., Billinton, A., et al. (2008) · Pain · doi:10.1016/j.pain.2008.04.006 · Cited by 270
“Given the therapeutic potential of CB1 and CB2 agonists as analgesic and anti-inflammatory agents [9], it would seem logical to postulate that the modulation of the GPR55 receptor may also produce analgesic activity.”
Background
Metadata
- Authors
- Fox, A., & Bevan, S.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa Healthcare
- Published
- 2005-06
- Volume
- 14
- Issue
- 6
- Pages
- 695-703
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2000895369
- Cited by
- 60
- References
- 19
- FWCI
- 4.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.